Nurix Therapeutics, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 3 insiders sold shares within a monthSince Oct 30, 2026+9.2
Trials
- NRIXNurix Therapeutics, Inc.9Calm
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Signing up patientsPhase 1/2150 patientsMain results: May 2033 - NRIXNurix Therapeutics, Inc.9Calm
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Signing up patientsPhase 2100 patientsMain results: Jan 2028 - NRIXNurix Therapeutics, Inc.9Calm
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Signing up patientsPhase 3620 patientsMain results: Oct 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
28 sales (6 not pre-planned) · 0 purchases
- van Houte HansChief Financial Officer · Nov 4, 2026Sold 3,300 sharesabout $51 thousand · pre-planned
- van Houte HansChief Financial Officer · Nov 4, 2026Sold 1,469 sharesabout $24 thousand · pre-planned
- Ring ChristineChief Legal Officer · Nov 3, 2026Sold 6,113 sharesabout $158 thousand · pre-planned
- Ring ChristineChief Legal Officer · Nov 2, 2026Sold 9,527 sharesabout $245 thousand · pre-planned
- Ring ChristineChief Legal Officer · Nov 2, 2026Sold 1,075 sharesabout $29 thousand · pre-planned
- Hansen GwennChief Scientific Officer · Nov 2, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.